v3.25.2
Balance Sheet Components - Intangible Assets, Net (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Finite-lived assets, net of accumulated amortization of $4,053 and $2,719, as of June 30, 2025 and December 31, 2024, respectively $ 23,453     $ 23,453   $ 24,787
Accumulated amortization 4,053     4,053   2,719
Indefinite-lived assets - in-process research and development 28,859     28,859   28,859
Total Intangible assets, net 52,312     52,312   $ 53,646
Amortization expense, Finite-lived intangible assets $ 600 $ 700   1,300 $ 1,600  
Impairment of out-license asset and remeasurement of CVR liability, net         $ 6,772  
Impairment charge       $ 0    
Surface Acquisition            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Fair value of the contingent consideration     $ 3,800      
Contingent consideration, current     0      
Novartis Institutes | Surface Acquisition            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Impairment of out-license asset and remeasurement of CVR liability, net     $ 6,800      
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]     Selling, General and Administrative Expense      
Impairment charge     $ 10,600